Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
Bright Minds Biosciences, a biotech firm specializing in treatments for neuropsychiatric disorders, epilepsy, and pain, announced a presentation at the LD Micro Main Event on October 12, 2021, at 12:30 PM PT. CEO Ian McDonald will lead the presentation, accessible via a webcast. Additionally, the management team will meet with institutional investors at the conference. Following the event, a replay of the presentation will be available on the company’s website for 90 days. Bright Minds aims to develop next-generation serotonin agonists with fewer side effects.
- None.
- None.
VANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright Minds, will present at the LD Micro Main Event Small Cap Investment Conference as follows:
| Date: | Tuesday, October 12, 2021 |
| Time: | 12:30PM PT/3:30PM ET |
| Webcast: | https://me21.mysequire.com/ |
Bright Minds’ management team will also be conducting meetings with institutional investors throughout the conference. To schedule a meeting, please visit https://www.meetmax.com/sched/event_76871/conference_home.html.
An archived replay of the presentation will be available on the Company’s website immediately following the conference and will be available for 90 days at: https://brightmindsbio.com/investors/.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Investor Contact:
Lisa Wilson
E: lwilson@insitecony.com
In-Site Communications, Inc.
T: +1-917-543-9932
FAQ
When is Bright Minds Biosciences presenting at the LD Micro Main Event?
Where can I watch the Bright Minds Biosciences presentation?
What is the focus of Bright Minds Biosciences?
How long will the presentation replay be available?
What conference will Bright Minds Biosciences attend for investor meetings?
